455 related articles for article (PubMed ID: 10222191)
21. Backbone dynamics of the CDK inhibitor p19(INK4d) studied by 15N NMR relaxation experiments at two field strengths.
Renner C; Baumgartner R; Noegel AA; Holak TA
J Mol Biol; 1998; 283(1):221-9. PubMed ID: 9761685
[TBL] [Abstract][Full Text] [Related]
22. Influence of human p16(INK4) and p21(CIP1) on the in vitro activity of recombinant Plasmodium falciparum cyclin-dependent protein kinases.
Li Z; Le Roch K; Geyer JA; Woodard CL; Prigge ST; Koh J; Doerig C; Waters NC
Biochem Biophys Res Commun; 2001 Nov; 288(5):1207-11. PubMed ID: 11700040
[TBL] [Abstract][Full Text] [Related]
23. Cyclin-dependent kinases: engines, clocks, and microprocessors.
Morgan DO
Annu Rev Cell Dev Biol; 1997; 13():261-91. PubMed ID: 9442875
[TBL] [Abstract][Full Text] [Related]
24. Principles of CDK regulation.
Morgan DO
Nature; 1995 Mar; 374(6518):131-4. PubMed ID: 7877684
[TBL] [Abstract][Full Text] [Related]
25. Cyclin-dependent kinases: inhibition and substrate recognition.
Endicott JA; Noble ME; Tucker JA
Curr Opin Struct Biol; 1999 Dec; 9(6):738-44. PubMed ID: 10607671
[TBL] [Abstract][Full Text] [Related]
26. Recent developments in cyclin-dependent kinase biochemical and structural studies.
Echalier A; Endicott JA; Noble ME
Biochim Biophys Acta; 2010 Mar; 1804(3):511-9. PubMed ID: 19822225
[TBL] [Abstract][Full Text] [Related]
27. p21 is a component of active cell cycle kinases.
Zhang H; Hannon GJ; Casso D; Beach D
Cold Spring Harb Symp Quant Biol; 1994; 59():21-9. PubMed ID: 7587072
[No Abstract] [Full Text] [Related]
28. Structural insights into the functional diversity of the CDK-cyclin family.
Wood DJ; Endicott JA
Open Biol; 2018 Sep; 8(9):. PubMed ID: 30185601
[TBL] [Abstract][Full Text] [Related]
29. Expression and Purification of Recombinant Cyclins and CDKs for Activity Evaluation.
Gallastegui E; Bachs O
Methods Mol Biol; 2016; 1336():9-12. PubMed ID: 26231704
[TBL] [Abstract][Full Text] [Related]
30. Structural dissection of cyclin dependent kinases regulation and protein recognition properties.
Lolli G
Cell Cycle; 2010 Apr; 9(8):1551-61. PubMed ID: 20372077
[TBL] [Abstract][Full Text] [Related]
31. Measurement of plant cyclin-dependent kinase activity using immunoprecipitation-coupled and affinity purification-based kinase assays and the baculovirus expression system.
Harashima H; Sekine M
Methods Mol Biol; 2011; 779():65-78. PubMed ID: 21837561
[TBL] [Abstract][Full Text] [Related]
32. Regulation of cyclin-Cdk activity in mammalian cells.
Obaya AJ; Sedivy JM
Cell Mol Life Sci; 2002 Jan; 59(1):126-42. PubMed ID: 11846025
[TBL] [Abstract][Full Text] [Related]
33. Cyclin-cyclin-dependent kinase regulatory response is linked to substrate recognition.
Cuomo ME; Platt GM; Pearl LH; Mittnacht S
J Biol Chem; 2011 Mar; 286(11):9713-25. PubMed ID: 21233209
[TBL] [Abstract][Full Text] [Related]
34. Intrinsic disorder mediates the diverse regulatory functions of the Cdk inhibitor p21.
Wang Y; Fisher JC; Mathew R; Ou L; Otieno S; Sublet J; Xiao L; Chen J; Roussel MF; Kriwacki RW
Nat Chem Biol; 2011 Apr; 7(4):214-21. PubMed ID: 21358637
[TBL] [Abstract][Full Text] [Related]
35. Structure and inhibitor specificity of the PCTAIRE-family kinase CDK16.
Dixon-Clarke SE; Shehata SN; Krojer T; Sharpe TD; von Delft F; Sakamoto K; Bullock AN
Biochem J; 2017 Feb; 474(5):699-713. PubMed ID: 28057719
[TBL] [Abstract][Full Text] [Related]
36. The influence of reactive oxygen species on cell cycle progression in mammalian cells.
Verbon EH; Post JA; Boonstra J
Gene; 2012 Dec; 511(1):1-6. PubMed ID: 22981713
[TBL] [Abstract][Full Text] [Related]
37. Cyclin H activation and drug susceptibility of the Pfmrk cyclin dependent protein kinase from Plasmodium falciparum.
Waters NC; Woodard CL; Prigge ST
Mol Biochem Parasitol; 2000 Mar; 107(1):45-55. PubMed ID: 10717301
[TBL] [Abstract][Full Text] [Related]
38. Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors.
Kalra S; Joshi G; Munshi A; Kumar R
Eur J Med Chem; 2017 Dec; 142():424-458. PubMed ID: 28911822
[TBL] [Abstract][Full Text] [Related]
39. CDKs and CKIs: molecular targets for tissue remodelling.
Nabel EG
Nat Rev Drug Discov; 2002 Aug; 1(8):587-98. PubMed ID: 12402499
[TBL] [Abstract][Full Text] [Related]
40. Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics.
Fischer PM; Lane DP
Curr Med Chem; 2000 Dec; 7(12):1213-45. PubMed ID: 11032968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
